20 completed, 3 terminated, 3 unknown, 2 recruiting. 10 Phase 2, 8 Not applicable, 6 Phase 1, 5 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 9, Terminated 1 |
| Not applicable | 8 | Completed 4, Terminated 2, Unknown 2 |
| Phase 1 | 6 | Completed 6 |
| Phase 3 | 5 | Completed 4, Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Cysteamine: new trials by email Literature Review of Cysteamine trials Research Report on Cysteamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of a Bilayering Serum and Cream Containing GABA, DMAE, Cysteamine, and Bakuchiol for Skin Whitening and Anti-Aging GABA, Placebo, DMAE - Skin Aging | Phase 2 | Completed | Hasanuddin University | 44 | 2025-03-12 | 2026-03-24 |
| PK and PD Study of NPI-001 and Cysteamine Bitartrate Cysteamine Bitartrate, N-Acetylcysteine Amide - Cystinosis | Phase 1 / Phase 2 | Completed | Nacuity Pharmaceuticals, Inc. | 8 | 2023-10-29 | 2026-10-13 |
| Combination Topical Cysteamine and Fractional 1927nm Low-Powered Diode Laser for Treatment of Facial Melasma Fractional 1927nm Low-Powered Diode Laser, Topical Cysteamine - Melasma | Not applicable | Unknown | UnionDerm | 20 | 2022-10-28 | 2022-12-19 |
| Efficacy and Safety of Topical Cysteamine for Postinflammatory Hyperpigmentation Topical Cysteamine, Topical Vehicle Control - Hyperpigmentation; Postinflammatory | Not applicable | Unknown | Chang Gung Memorial Hospital | 40 | 2021-12-10 | 2022-01-25 |
| Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2) Mercaptamine - Cystinosis | Phase 3 | Completed | RECORDATI GROUP | 5 | 2020-09-01 | 2024-02-05 |
| Observational Study to Assess the Quality of Life in Nephropathic Cystinosis Patients Cysteamine Bitartrate - Nephropathic Cystinosis | Unknown | Chiesi SA/NV | 31 | 2020-07-31 | 2021-11-29 | |
| Cysteamine for Asthma Cysteamine Bitartrate, Placebo Oral Tablet - Asthma | Phase 1 | Completed | Children's Hospital Medical Center, Cincinnati | 60 | 2019-06-18 | 2021-05-06 |
| A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations Cysteamine, Placebo Oral Capsule - Cystic Fibrosis | Phase 2 | Completed | NovaBiotics Ltd. | 91 | 2016-12-01 | 2021-04-14 |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam - Community-acquired Pneumonia, Influenza, COVID-19 | Phase 3 | Recruiting | UMC Utrecht | 20000 | 2016-04-11 | 2024-07-12 |
| A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease Cysteamine Bitartrate - Mitochondrial Diseases | Phase 2 | Terminated | Amgen | 22 | 2015-05-19 | 2024-12-27 |
| First Study of Oral Cysteamine in Cystic Fibrosis Cysteamine - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | University of Aberdeen | 10 | 2014-08-01 | 2015-11-05 |
| Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease Cysteamine Bitartrate - Inherited Mitochondrial Disease, Including Leigh Syndrome | Phase 2 | Completed | Amgen | 36 | 2014-05-01 | 2024-12-27 |
| Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis RP103, Cystagon® - Cystinosis | Phase 3 | Completed | Amgen | 41 | 2013-01-31 | 2024-12-27 |
| A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications Cysteamine bitartrate - Cystinosis | Not applicable | Completed | Hospices Civils de Lyon | 65 | 2011-12-01 | 2025-12-19 |
| Study in Healthy Adults to Determine the Effect That Food Has on the Absorption and Delivery of the Drug Cystagon™ Cysteamine bitartrate - Cystinosis, Nephropathic Cystinosis | Not applicable | Completed | University of California, San Diego | 8 | 2011-09-01 | 2013-10-09 |
| Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) Cysteamine Bitartrate Delayed-release Capsules - Cystinosis | Phase 3 | Completed | Amgen | 60 | 2010-08-27 | 2024-12-27 |
| Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis Cystagon® (Cysteamine Bitartrate), Cysteamine Bitartrate Delayed-release Capsules (RP103) - Cystinosis | Phase 3 | Completed | Amgen | 43 | 2010-06-01 | 2024-12-19 |
| An Open Trial of Cysteamine Treatment in Schizophrenia (Cystagon) Cysteamine Bitartrate - Schizophrenia, Schizoaffective | Not applicable | Terminated | Augusta University | 3 | 2009-09-01 | 2014-11-20 |
| Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis Cystagon®, RP103 - Cystinosis | Phase 1 / Phase 2 | Completed | Amgen | 9 | 2009-05-01 | 2024-12-19 |
| A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH) Cysteamine - Fatty Liver | Phase 1 / Phase 2 | Completed | Joel Lavine | 13 | 2008-10-01 | 2014-01-31 |
Showing 20 of 28. Sign in to see all of them.
Cystinosis (14) · Rare Diseases (5) · Metabolic Diseases (4) · Cystic Fibrosis (2) · Epilepsies, Myoclonic (2) · Leigh Disease (2) · Lung Diseases (2) · Mitochondrial Encephalomyopathies (2) · Ophthalmoplegia, Chronic Progressive External (2) · Optic Atrophy, Hereditary, Leber (2) · Pneumonia (2) · AIDS-Related Complex (1) · Acidosis, Lactic (1) · Asthma (1) · Bacterial Infections (1)
Amgen (6) · National Eye Institute (NEI) (2) · Augusta University (1) · Chang Gung Memorial Hospital (1) · Chiesi SA/NV (1) · Children's Hospital Medical Center, Cincinnati (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · FDA Office of Orphan Products Development (1) · Hasanuddin University (1) · Hospices Civils de Lyon (1) · Icahn School of Medicine at Mount Sinai (1) · Joel Lavine (1) · Mylan Laboratories (1) · Nacuity Pharmaceuticals, Inc. (1) · National Human Genome Research Institute (NHGRI) (1)
United States (19) · France (6) · United Kingdom (5) · Belgium (4) · Italy (4) · Netherlands (4) · Australia (2) · Germany (2) · Canada (1) · Colombia (1) · Croatia (1) · Czechia (1) · Estonia (1) · Finland (1) · Hungary (1)
Anil B Mukherjee, M.D. (1) · Cochat Pierre, PUPH (1) · Colin McArthur, Dr (1) · Derek Angus, Prof (1) · Edward F. Lemanowicz (1) · Graham Devereux, MD (1) · Gurjit K Khurana Hershey, MD, PhD (1) · Hugh McCarthy, PhD, FRACP (1) · James Murrough, MD (1) · John Marshall, Prof (1) · Lennie Derde, MD (1) · Marc Bonten, Prof (1) · Peter Buckley, M.D. (1) · Rachel J Bishop, M.D. (1)
PMID 21395631, PMID 24948347, PMID 24997880, PMID 25251767, PMID 28057644, PMID 28678558, PMID 32267771, PMID 32585079, PMID 32876697, PMID 32879998, PMID 32901297, PMID 32981068, PMID 33370348, PMID 33394942, PMID 33509275, PMID 33631065, PMID 34251506, PMID 34351721, PMID 34351722, PMID 34473343, PMID 34591360, PMID 34606578, PMID 35315874, PMID 36942550, PMID 36967714, PMID 37039790, PMID 37489818, PMID 37877585, PMID 37888913, PMID 40261382, PMID 40360262, PMID 42823695
2014 (1), 2015 (1), 2023 (1)